Irritable Bowel Syndrome News

The FDA has announced its approval of two new treatments for adult patients with diarrhea-predominant irritable bowel syndrome.

WASHINGTON — Michael Epstein, MD, senior medical advisor for IMHealthScience, discusses his presentation on IBgard, a new medical food product for the treatment of diarrhea-predominant and mixed-symptom irritable bowel syndrome. According to a press release, IBgard works by delivering peppermint oil to the lower gut.

Researchers have completed the first large-scale validation of anti-cytolethal distending toxin B and anti-vinculin antibodies as a mechanism-based biomarker for diarrhea-predominant irritable bowel syndrome, according to data released in advance of Digestive Disease Week.

Constipation-predominant irritable bowel syndrome, or IBS-C, and chronic idiopathic constipation, or CIC, are not distinct diseases but rather exist on a spectrum where abdominal symptoms affect the most severe patients, according to recent study data.

The incidence of ischemic colitis has increased in recent decades and is most common in older patients with multiple comorbidities, according to findings from a retrospective population-based cohort and nested case-control study.

Confident diagnosis of irritable bowel syndrome depends on symptom-based criteria, and successful management relies on a holistic approach and a trusting patient-physician relationship, according to a recent clinical review.

Mesalazine was not superior to placebo in relieving symptoms of diarrhea-predominant irritable bowel syndrome, according to recent study data.

Adding C-reactive protein and fecal calprotectin to symptom-based diagnostic criteria may help to rule out inflammatory bowel disease in patients with symptoms of irritable bowel syndrome, according to new research data.

The American Gastroenterological Association Research Foundation has announced receipt of a philanthropic donation that will fund an award to advance research in neuroenteric disease, according to a press release.

Orca Pharmaceuticals and AstraZeneca have announced the establishment of a 3-year partnership to investigate retinoic acid-related orphan nuclear receptor gamma inhibitors with the goal of creating an oral treatment for autoimmune diseases.